Evidence map›Paper›PMID 27634224›Full record

Trial reportDiabetes2017

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial.

Piero Ruggenenti, Manuela Abbate, Barbara Ruggiero, Stefano Rota, Matias Trillini, Carolina Aparicio, Aneliya Parvanova, Ilian Petrov Iliev, Giovanna Pisanu, Annalisa Perna and 10 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Measurement, Estimation, and Correlates of the GFR before and after Bariatric Surgery.Journal of the American Society of Nephrology : JASN · 2026
    Article
  11. Article
  12. Article
  13. Obesity and Metabolic Health in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Review
  14. Article
  15. Review
  16. Glomerular hyperfiltration as a therapeutic target for CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Piero RuggenentiIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Manuela AbbateIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Barbara RuggieroIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Stefano RotaUnit of Nephrology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Matias TrilliniIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Carolina AparicioIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Aneliya ParvanovaIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Ilian Petrov IlievIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Giovanna PisanuIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Annalisa PernaIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Angela RussoIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Olimpia DiadeiIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Davide MartinettiIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Antonio CannataIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Fabiola CarraraIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Silvia FerrariIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Nadia StucchiIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy.
Giuseppe RemuzziIRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Bergamo, Italy giuseppe.remuzzi@marionegri.it.
Luigi FontanaDepartment of Clinical and Experimental Sciences, Brescia University Medical School, Brescia, Italy.
C.RE.S.O. Study Group
Mario Negri Institute for Pharmacological Research · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Papa Giovanni XXIII · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In individuals with type 2 diabetes with abdominal obesity, hyperfiltration is a risk factor for accelerated glomerular filtration rate (GFR) decline and nephropathy. In this academic, single-center, parallel-group, prospective, randomized, open-label, blinded end point trial, consenting patients with type 2 diabetes aged >18 years, with waist circumference >94 (males) or >80 (females) cm, serum creatinine <1.2 mg/dL, and normoalbuminuria were randomized (1:1) with permuted blocks to 6 months of a 25% calorie restricted (CR) or standard diet (SD). Primary outcome was measured GFR (iohexol plasma clearance). Analyses were by modified intention to treat. At 6 months, GFR significantly decreased in 34 patients on CR and did not change appreciably in 36 on SD. Changes were significantly different between the groups. GFR and body weight reduction were correlated. GFR reduction was larger in hyperfiltering (GFR >120 mL/min) than nonhyperfiltering patients and was associated with BMI, waist circumference, blood pressure, heart rate, HbA

Indexed as

Caloric RestrictionAgedAngiotensin IIBody WeightC-Reactive ProteinDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateHumansKidneyKidney Function TestsMaleMiddle AgedObesity, AbdominalRisk FactorsAngiotensin IIC-Reactive Protein

Identifiers

PMID27634224
OpenAlexW2460846739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.